Zobrazeno 1 - 10
of 146
pro vyhledávání: ''
Autor:
Jessica Liu, Paul Frankel, Marice Alcantara, Przemyslaw Twardowski, Marcin Kortylewski, Tanya B. Dorff, S.V. Dandapani
Publikováno v:
Cancer Research. 81:677-677
Prostate cancer is the second leading cause of death in men in the developed countries. Androgen deprivation therapy (ADT) is commonly used to treat prostate tumors at earlier stages due to hormone-dependence of cancer cells. However, the onset of an
Publikováno v:
Cancer Research. 80:6450-6450
Hepsin, a type II transmembrane serine protease, is commonly overexpressed in a variety of epithelial cancers, where its overexpression and concurrent proteolytic activity correlate with tumor progression. Recent studies indicate that Hepsin undergoe
Autor:
Jeffery L. Werbin, Daniel E. Sabath, Celestia S. Higano, Daniel Campton, Heather Itamoto, Tanisha Mojica, Ryan Houston, Edward Lo, Vijayakrishna K. Gadi, Alisa Clein, Brady Gardner, Eric Kaldjian, Lillian Costandy, Arturo Ramirez, Tad George
Publikováno v:
Cancer Research. 80:6442-6442
Enumeration and phenotypic profiling of circulating tumor cells (CTCs) can give important information about tumor progression, presence of therapeutic targets, and metastatic potential. New and informative cancer-specific biomarkers are being discove
Autor:
Véronique Lefebvre, Soma Sannigrahi, Adeboye O. Osunkoya, W. Guy Wiles, Birdal Bilir, W. David Martin, Daniel Metzger, Carlos S. Moreno, Demetri D. Spyropoulos
Publikováno v:
Cancer Research. 76:1112-1121
Understanding remains incomplete of the mechanisms underlying initiation and progression of prostate cancer, the most commonly diagnosed cancer in American men. The transcription factor SOX4 is overexpressed in many human cancers, including prostate
Autor:
Alexander R. A. Anderson, Gustavo Ayala, Ziv Frankenstein, Simon W. Hayward, David Basanta, Omar E. Franco
Publikováno v:
Cancer Research. 75:B2-53
Prostate cancer (PCa) is ranks fourth in worldwide cancer incidence. Gleason (epithelial cancer marker) is the standard metric for defining prostate cancer aggressiveness. Still, PCa is difficult to predict using available prognostic data. Stromal-tu
Autor:
Renjie Jin, Robert J. Matusik, Tatsuki Koyama, Joseph A. Smith, Peter E. Clark, Yajun Yi, Fiona E. Yull, Timothy S. Blackwell
Publikováno v:
Cancer Research. 74:2763-2772
In many patients with prostate cancer, the cancer will be recurrent and eventually progress to lethal metastatic disease after primary treatment, such as surgery or radiation therapy. Therefore, it would be beneficial to better predict which patients
Autor:
Kimya Jones, Ravindra Kolhe, Benjamin W Johnson, Chetan Pundkar, Pankaj Ahluwalia, Ashis K. Mondal, Saleh Heneidi
Publikováno v:
Cancer Research. 79:1161-1161
Colorectal cancer (CRC) is third deadliest cancer in United States, only behind lung and prostate cancer. Although several therapies are available to treat colorectal cancer but there is need for new prognostic biomarkers to tailor appropriate person
Autor:
Keiran S.M. Smalley, Robert A. Gatenby, Alexander R. A. Anderson, Jingsong Zhang, Jill Gallaher, Zeynep Eroglu, Mark Robertson-Tessi, Inna Smalley, Eunjung Kim
Publikováno v:
Cancer Research. 79:SY38-02
Introduction: Over the past decade, there has been an explosion of new, targeted therapies for cancer. However, for advanced disease, having a vast arsenal of treatment options does not always lead to sustained outcomes. Targeted treatments are too s
Autor:
Christian G. Stief, Harald Hessel, Günter Schmidt, Nathalie Harder, Thomas Kirchner, Ralf Huss, Maria Athelogou, Tze Heng Tan, Alexander Buchner
Publikováno v:
Cancer Research. 78:A069-A069
Introduction: The composition of different immune cell populations in the tumor microenvironment plays an important role for tumor progression in various cancer types. In particular, tumor-associated macrophages (TAMs) and tumor-infiltrating T cells
Autor:
R. Jeffrey Karnes, George Vasmatzis, John C. Cheville, Farhad Kosari, Shabnam Zarei, William R. Sukov, Stephen J. Murphy, Irina V. Kovtun, Sarah H. Johnson
Publikováno v:
Cancer Research. 73:3275-3284
Gleason score 7 (GS7) prostate cancer [tumors with both Gleason patterns 3 (GP3) and 4 (GP4)] portends a significantly more aggressive tumor than Gleason score 6 (GS6). It is, therefore, critical to understand the molecular relationship of adjacent G